HC Wainwright Reaffirms Neutral Rating for Sarepta Therapeutics (NASDAQ:SRPT)

HC Wainwright reiterated their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT - Free Report) in a report released on Wednesday,Benzinga reports. They currently have a $75.00 price objective on the biotechnology company's stock.

Several other research firms have also recently commented on SRPT. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $163.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Morgan Stanley lowered their target price on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating on the stock in a research note on Friday, April 11th. Wells Fargo & Company began coverage on shares of Sarepta Therapeutics in a research note on Friday, April 11th. They issued an "overweight" rating and a $115.00 price target for the company. Needham & Company LLC lowered their price objective on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating on the stock in a research report on Thursday, April 3rd. Finally, Scotiabank dropped their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a report on Thursday, March 20th. Six investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $161.83.

Sarepta Therapeutics Stock Down 0.3 %

Shares of SRPT traded down $0.15 on Wednesday, hitting $53.79. 1,912,278 shares of the stock traded hands, compared to its average volume of 1,410,388. The company has a market capitalization of $5.22 billion, a PE ratio of 43.03 and a beta of 0.93. Sarepta Therapeutics has a one year low of $48.01 and a one year high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The business has a 50 day simple moving average of $82.21 and a 200 day simple moving average of $107.88.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Capital International Investors lifted its stake in shares of Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after purchasing an additional 2,437,855 shares during the last quarter. Norges Bank bought a new stake in Sarepta Therapeutics in the fourth quarter worth $126,315,000. Assenagon Asset Management S.A. boosted its stake in Sarepta Therapeutics by 438.0% during the first quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company's stock worth $45,477,000 after buying an additional 580,123 shares during the period. Farallon Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 11.1% in the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock valued at $348,368,000 after acquiring an additional 285,100 shares during the period. Finally, Vestal Point Capital LP bought a new stake in shares of Sarepta Therapeutics in the 4th quarter worth about $30,398,000. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.